CD22 and lymphoma: The crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.50 Preclinical studies demonstrated that CD22 mAbs had independent lymphomacidal properties.51 Single-agent epratuzumab has been investigated in both indolent and aggressive NHLs.